An ongoing axSpA cohort in Netherlands study assessed the rate of progression of nr-axSpA to AS patients over a 6 y period Every 2 y approximately 10% of patients progressed from nr-axSpA to AS Abst # 0907 #ACR21 @RheumNow https://t.co/gGhhssLS5N